drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
A HER2-directed antibody–drug conjugate composed of a humanized anti-HER2 IgG1 (disitamab) linked to the microtubule inhibitor monomethyl auristatin E (MMAE, vedotin). After binding HER2 on tumor cells and internalization, MMAE is released to disrupt microtubules, inducing G2/M arrest and apoptosis, with potential bystander effect and Fc-mediated ADCC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-HER2 IgG1 (disitamab) linked to the microtubule inhibitor MMAE (vedotin). After binding HER2 on tumor cells and internalization, the linker is cleaved to release MMAE, which disrupts microtubules, causing G2/M arrest and apoptosis; membrane-permeable MMAE can exert a bystander effect, and the IgG1 Fc may mediate ADCC.
drug_name
Disitamab vedotin (RC48)
nct_id_drug_ref
NCT06561555